Phaseline

Companies › Biocomposites

Biocomposites: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Immunology, Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
STIMULAN VG
Bioabsorbable composite of gentamicin and calcium sulfate
–Phase 2Diabetic Foot Osteomyelitis; Pressure Ulcer, Stage IVDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05539963STIMULAN VGPhase 2Diabetic Foot OsteomyelitisMetabolic and endocrineJun 2026
NCT06283979STIMULAN VGPhase 2Pressure Ulcer, Stage IVImmunologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Red de Terapia Celular Tiger Biosciences Immunis Nature Cell Throne Biotechnologies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.